Combined Hepatocellular and Cholangiocarcinoma
3
1
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Gemcitabine
Research Leaders
12 sponsors active, led by Eastern Hepatobiliary Surgery Hospital
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Research Network
Common Treatments
- Gemcitabine1
- Interventional Therapies Combined With Or Without Systemic Drugs1
- Tremelimumab1
- Cisplatin1
- Durvalumab1
Active Sponsors
- Eastern Hepatobiliary Surgery Hospital1
- AstraZeneca1
- Sun Yat-Sen University Cancer Center1
- Zhejiang Cancer Hospital1
- Mehmet Akce1
Top Investigators
University of Alabama at Birmingham
Zhongda hospital, Southeast university, Nanjing, China
Basilea Pharmaceutica International Ltd, Allschwil
Related Conditions
- Combined Hepatocellularcholangiocarcinoma1
- Intrahepatic Cholangiocarcinoma1
- Combined Hepatocellular Carcinoma And Cholangiocarcinoma1